転写因子TFAP2Aは,PRAME転写を活性化することによって,三重陰性乳がんの成長と転移を誘導し,フェロプトーシスを阻害する.
PubMedで要約を見る
まとめ
この要約は機械生成です。転写因子AP- 2α (TFAP2A) は,PRAMEを活性化し,フェロプトーシスを抑制することで,トリプルネガティブ乳がん (TNBC) の進行を促進します. TFAP2AとPRAMEをターゲットにすることで,TNBCの潜在的な治療戦略が提供されます.
科学分野
- 腫瘍学
- 分子生物学
- 癌 の 遺伝子
背景
- トリプルネガティブ乳がん (TNBC) は高い再発率と死亡率を示しています.
- 転写因子AP- 2α (TFAP2A) は腫瘍の発症と進行に影響する.
- メラノーマにおける好ましい表現抗原 (PRAME) はTNBC細胞の侵入と移動を促進する.
研究 の 目的
- TNBCにおけるTFAP2AとPRAMEの役割を調査する.
- TFAP2A,PRAME,TNBCの進行を結びつける分子メカニズムを解明する.
主な方法
- 定量的なリアルタイムPCR (RT-qPCR) と,遺伝子とタンパク質発現分析のためのウェスタンブラット.
- 細胞の行動を評価するために,in vitro検査 (トランスウェル,傷の治癒,コロニー形成,フロー細胞測定) を行う.
- 染色体免疫降水 (ChIP) と二重ルシフェラーゼレポーターアッセイで,PRAMEプロモーターへのTFAP2A結合を確認する.
- 腫瘍の成長に対するTFAP2Aの効果を評価するためのインビオ異種移植モデル.
主要な成果
- TFAP2AとPRAMEはTNBC組織と細胞系において著しく上位調節された.
- TFAP2A欠乏症はTNBC細胞の侵入,移動,増殖を抑制し,アポトーシスとフェロプトーシスを誘発した.
- TFAP2AはPRAMEプロモーターに直接結合し,その転写活動を強化する.
- TFAP2Aのノックダウンにより,TNBC腫瘍の成長が vivoで抑制されました.
結論
- TFAP2AはPRAMEの転写因子として作用し,TNBCの悪性行動を促進します.
- TFAP2A活性化PRAMEはフェロプトーシスを抑制し,TNBCの進行に寄与する.
- TFAP2A-PRAME軸をターゲットにすることは,TNBCの有望な治療戦略です.
関連する概念動画
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

